Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...

Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. It’s also particularly ...

The global market for kinase inhibitors targeting ALK-mutated NSCLC is expected to reach $5.7 billion by 2031. Credit: ridersuperone via Shutterstock. At the 2025 European Society of Medical Oncology ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...